Study of gilteritinib with FLAI chemotherapy for FLT3-positive acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (gilteritinib plus a chemo regimen called FLAI) as the first treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The goal is to see if this combination helps destroy leukemia cells better and with acceptable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must be diagnosed with acute myeloid leukemia (AML) that has not been treated yet (except for a very basic medication to keep white blood cell counts in check).
- Your leukemia must have a specific gene change called a FLT3 mutation.
- You must be in fairly good overall health, able to perform daily activities (ECOG score 0-2).
- Your heart, kidneys, and liver must be working well enough, based on routine tests.
- You must agree to use effective birth control during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This study looks at how well new AML medicines work in everyday medical practice, outside of clinical trials. If you are starting a newer AML drug like gilteritinib, an IDH inhibitor, oral azacytidine, or others, you may be able to join.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.